Tandem Diabetes Care, Inc. (NASDAQ:TNDM) headquartered in San Diego, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.tandemdiabetes.com
Earnings Expectation
Tandem Diabetes Care, Inc. developer of medical devices for insulin-dependents, is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.1 per share from revenue of $ 115.15 million. Looking ahead, the full year loss are expected at $ 0.69 per share on the revenues of $ 462.16 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 450.00 million ~ $ 465.00 million
Click Here For More Historical Outlooks Of Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The companys flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pumps software.
